Browse News
Filter News
Found 6,999 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
4/18/2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.
-
Red Biotechnology Market Size, CAGR, Trends, Report 2024 to 2033
4/18/2024
According to Vision Research Reports, the global red biotechnology market size was estimated at around USD 492.74 billion in 2023
-
Biopharma Leaders Come Together at Veeva Commercial Summit to Advance Customer-Centric Engagement
4/17/2024
Veeva Systems (NYSE: VEEV) today announced that leaders from Bayer, Genentech, Novo Nordisk, Takeda, and others will be among the keynote speakers at the 2024 Veeva Commercial Summit, May 7-8 in Boston.
-
Oncology Market Size to Exceed USD 521.60 Billion by 2033 | CAGR 8.9%
4/16/2024
The global oncology market size was valued at USD 222.36 billion in 2023 and is poised to grow from USD 242.15 billion in 2024
-
Pharmacogenomics Market Size is Forecasted to Worth USD 35.67 Billion by 2032
4/15/2024
The global pharmacogenomics market size was reached at USD 15 billion in 2022 and is forecasted to be worth over USD 35.67 billion by 2032 with a CAGR of 9.1% from 2023 to 2032.
-
Neurvati Neurosciences Announces Appointment of Deborah Dunsire, MD, as Member and Chair of Company Board of Directors
4/15/2024
Neurvati Neurosciences today announced the appointment of Dr. Deborah Dunsire as a new member and the new chair of the company's board of directors.
-
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
4/11/2024
Orna Therapeutics today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer.
-
Top 5 Companies Hiring in San Diego
4/11/2024
Looking for a biopharma job in San Diego? Check out these top five companies hiring life sciences professionals like you. -
Crescendo Biologics presents preclinical data on lead clinical candidate CB307 and unveils its first ‘2 in 1’ immune cell engager CB699 at AACR 2024
4/10/2024
Crescendo Biologics Ltd has presented preclinical data at the 2024 American Association for Cancer Research Annual Meeting on its two leading programmes.
-
Allogeneic Cell Therapy Devices Market Poised for Significant Growth
4/8/2024
The global allogeneic cell therapy devices market is growing at a strongest CAGR of 25.28% from 2023 to 2032.
-
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
4/8/2024
Takeda announced the selection of eight new U.S. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its FY2023 U.S. Corporate Social Responsibility program.
-
Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
4/8/2024
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
-
U.S. Cell And Gene Therapy Clinical Trial Services industry is Rising Rapidly
4/5/2024
The U.S. cell and gene therapy clinical trial services market size was valued at USD 9.10 billion in 2023 and is anticipated to reach around USD 71.54 billion by 2033, growing at a CAGR of 22.9% from 2024 to 2033.
-
The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.
-
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
4/4/2024
Ovid Therapeutics Inc. today announced that management will participate in a virtual presentation at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 9:30 a.m. ET.
-
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
-
C-Suite Shuffle: Lonza Hires New CEO
4/3/2024
Read the latest overview of people coming and going from executive positions at biopharma companies that BioSpace covers. -
Neurocrine Biosciences Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder
4/3/2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder.